共 50 条
Clarithromycin Solid Lipid Nanoparticles for Topical Ocular Therapy: Optimization, Evaluation, and In Vivo Studies
被引:72
作者:
Nair, Anroop B.
[1
]
Shah, Jigar
[2
]
Al-Dhubiab, Bandar E.
[1
]
Jacob, Shery
[3
]
Patel, Snehal S.
[4
]
Venugopala, Katharigatta N.
[1
,5
]
Morsy, Mohamed A.
[1
,6
]
Gupta, Sumeet
[7
]
Attimarad, Mahesh
[1
]
Sreeharsha, Nagaraja
[1
,8
]
Shinu, Pottathil
[9
]
机构:
[1] King Faisal Univ, Dept Pharmaceut Sci, Coll Clin Pharm, Al Hasa 31982, Saudi Arabia
[2] Nirma Univ, Inst Pharm, Dept Pharmaceut, Ahmadabad 382481, Gujarat, India
[3] Gulf Med Univ, Dept Pharmaceut Sci, Coll Pharm, Ajman 4184, U Arab Emirates
[4] Nirma Univ, Inst Pharm, Dept Pharmacol, Ahmadabad 382481, Gujarat, India
[5] Durban Univ Technol, Dept Biotechnol & Food Technol, ZA-4000 Durban, Natal, South Africa
[6] Menia Univ, Fac Med, Dept Pharmacol, El Minia 61511, Egypt
[7] Maharishi Markandeshwar Deemed Univ, MM Coll Pharm, Dept Pharmacol, Mullana 133203, India
[8] Vidya Siri Coll Pharm, Dept Pharmaceut, Off Sarjapura Rd, Bangalore 560035, Karnataka, India
[9] King Faisal Univ, Dept Biomed Sci, Coll Clin Pharm, Al Hasa 31982, Saudi Arabia
关键词:
clarithromycin;
solid lipid nanoparticles;
optimization;
permeation;
pharmacokinetics;
DELIVERY-SYSTEM;
DRUG-DELIVERY;
CARRIERS NLC;
PHARMACOKINETICS;
SLN;
RELEASE;
EYE;
PENETRATION;
FORMULATION;
DESIGN;
D O I:
10.3390/pharmaceutics13040523
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
Solid lipid nanoparticles (SLNs) are being extensively exploited as topical ocular carrier systems to enhance the bioavailability of drugs. This study investigated the prospects of drug-loaded SLNs to increase the ocular permeation and improve the therapeutic potential of clarithromycin in topical ocular therapy. SLNs were formulated by high-speed stirring and the ultra-sonication method. Solubility studies were carried out to select stearic acid as lipid former, Tween 80 as surfactant, and Transcutol P as cosurfactant. Clarithromycin-loaded SLN were optimized by fractional factorial screening and 3(2) full factorial designs. Optimized SLNs (CL10) were evaluated for stability, morphology, permeation, irritation, and ocular pharmacokinetics in rabbits. Fractional factorial screening design signifies that the sonication time and amount of lipid affect the SLN formulation. A 3(2) full factorial design established that both factors had significant influences on particle size, percent entrapment efficiency, and percent drug loading of SLNs. The release profile of SLNs (CL9) showed similar to 80% drug release in 8 h and followed Weibull model kinetics. Optimized SLNs (CL10) showed significantly higher permeation (30.45 mu g/cm(2)/h; p < 0.0001) as compared to control (solution). CL10 showed spherical shape and good stability and was found non-irritant for ocular administration. Pharmacokinetics data demonstrated significant improvement of clarithromycin bioavailability (p < 0.0001) from CL10, as evidenced by a 150% increase in C-max (similar to 1066 ng/mL) and a 2.8-fold improvement in AUC (5736 ng h/mL) (p < 0.0001) as compared to control solution (C-max; 655 ng/mL and AUC; 2067 ng h/mL). In summary, the data observed here demonstrate the potential of developed SLNs to improve the ocular permeation and enhance the therapeutic potential of clarithromycin, and hence could be a viable drug delivery approach to treat endophthalmitis.
引用
收藏
页数:24
相关论文
共 50 条